AU2014209346B2 - Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid - Google Patents

Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid Download PDF

Info

Publication number
AU2014209346B2
AU2014209346B2 AU2014209346A AU2014209346A AU2014209346B2 AU 2014209346 B2 AU2014209346 B2 AU 2014209346B2 AU 2014209346 A AU2014209346 A AU 2014209346A AU 2014209346 A AU2014209346 A AU 2014209346A AU 2014209346 B2 AU2014209346 B2 AU 2014209346B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
corticosteroid
enhancing agent
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014209346A
Other languages
English (en)
Other versions
AU2014209346A1 (en
Inventor
Mahendra G. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Semnur Pharmaceuticals Inc
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of AU2014209346A1 publication Critical patent/AU2014209346A1/en
Application granted granted Critical
Publication of AU2014209346B2 publication Critical patent/AU2014209346B2/en
Priority to AU2019200649A priority Critical patent/AU2019200649B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AU2014209346A 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid Active AU2014209346B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200649A AU2019200649B2 (en) 2013-01-23 2019-01-31 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361755723P 2013-01-23 2013-01-23
US61/755,723 2013-01-23
US201361776617P 2013-03-11 2013-03-11
US61/776,617 2013-03-11
PCT/US2014/012824 WO2014116876A1 (en) 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200649A Division AU2019200649B2 (en) 2013-01-23 2019-01-31 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Publications (2)

Publication Number Publication Date
AU2014209346A1 AU2014209346A1 (en) 2015-07-23
AU2014209346B2 true AU2014209346B2 (en) 2018-11-15

Family

ID=50097866

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014209346A Active AU2014209346B2 (en) 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
AU2019200649A Active AU2019200649B2 (en) 2013-01-23 2019-01-31 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200649A Active AU2019200649B2 (en) 2013-01-23 2019-01-31 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Country Status (13)

Country Link
US (4) US9833460B2 (enExample)
EP (1) EP2948182B1 (enExample)
JP (1) JP6215354B2 (enExample)
KR (1) KR102055937B1 (enExample)
CN (1) CN105073138B (enExample)
AU (2) AU2014209346B2 (enExample)
BR (1) BR112015017246B1 (enExample)
CA (1) CA2897467C (enExample)
IL (1) IL239791B (enExample)
MX (1) MX366654B (enExample)
NZ (1) NZ709620A (enExample)
TW (1) TWI624262B (enExample)
WO (1) WO2014116876A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ， インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
TWI772659B (zh) * 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方
US11857554B2 (en) 2015-06-02 2024-01-02 Intravital Pty Ltd. Drug delivery device with pre-assembled cartridge
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022511030A (ja) * 2018-12-05 2022-01-28 アルデイラ セラピューティクス， インコーポレイテッド 注射可能な製剤
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CA3199093A1 (en) * 2020-10-22 2022-04-28 Pfizer Inc. Peg-free aqueous suspensions for parenteral administration of a corticosteroid
WO2024159191A1 (en) * 2023-01-26 2024-08-02 Insignia Pharmaceuticals, Llc Pharmaceutical compositions for treating osteoarthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
WO2009129148A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Methods and compositions for treating intervertebral disc herniations
WO2009139924A2 (en) * 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) * 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) * 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050186229A1 (en) 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) * 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
EP1968614A2 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) * 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
WO2010054356A1 (en) * 2008-11-10 2010-05-14 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of a corticosteroid
US8790702B2 (en) * 2009-07-30 2014-07-29 Carbylan Therapeutics, Inc. Modified hyaluronic acid polymer compositions and related methods
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
MX2014006056A (es) 2011-12-06 2014-08-08 Alcon Res Ltd Composicion de gel de celulosa con una mejor estabilidad de la viscosidad.
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ， インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
WO2009129148A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Methods and compositions for treating intervertebral disc herniations
WO2009139924A2 (en) * 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
TWI624262B (zh) 2018-05-21
MX366654B (es) 2019-07-17
US9833460B2 (en) 2017-12-05
CN105073138B (zh) 2018-06-05
KR20150114505A (ko) 2015-10-12
HK1218074A1 (zh) 2017-02-03
US10744144B2 (en) 2020-08-18
NZ709620A (en) 2020-07-31
US20220370476A1 (en) 2022-11-24
AU2019200649B2 (en) 2020-02-27
MX2015009455A (es) 2016-01-12
AU2014209346A1 (en) 2015-07-23
WO2014116876A8 (en) 2015-08-20
KR102055937B1 (ko) 2019-12-13
US12016867B2 (en) 2024-06-25
IL239791B (en) 2020-11-30
BR112015017246A8 (pt) 2019-10-29
EP2948182A1 (en) 2015-12-02
JP2016510329A (ja) 2016-04-07
CN105073138A (zh) 2015-11-18
EP2948182B1 (en) 2020-09-30
AU2019200649A1 (en) 2019-02-21
BR112015017246B1 (pt) 2022-11-29
US11364251B2 (en) 2022-06-21
US20180235980A1 (en) 2018-08-23
US20210052605A1 (en) 2021-02-25
WO2014116876A1 (en) 2014-07-31
BR112015017246A2 (pt) 2017-07-11
CA2897467C (en) 2020-09-22
CA2897467A1 (en) 2014-07-31
IL239791A0 (en) 2015-08-31
TW201442713A (zh) 2014-11-16
US20140356434A1 (en) 2014-12-04
JP6215354B2 (ja) 2017-10-18

Similar Documents

Publication Publication Date Title
US12016867B2 (en) Methods of treating inflammation and/or pain
US12285485B2 (en) Methods of treating pain
HK1218074B (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)